![Benita Prud’homme](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Cargos activos de Benita Prud’homme
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Lucida Medical Ltd.
![]() Lucida Medical Ltd. Medical SpecialtiesHealth Technology Lucida Medical Ltd. is a start-up based in Cambridge, UK that develops AI-based technology to assist clinicians in finding cancer more accurately, diagnosing and treating it more effectively, and saving time. The company was founded in 2019 by Dr. Antony Rix, an expert in medical devices, machine learning, and AI, and Prof. Evis Sala, who was a professor of oncological imaging at the University of Cambridge & Addenbrookes Hospital at the time. Lucida Medical's first product, Prostate Intelligence™ (PI™), is intended for use to assist in the diagnosis of prostate cancer and has completed regulatory approvals. The British company enables healthcare professionals to find cancer quickly and efficiently with artificial intelligence (AI) and magnetic resonance imaging (MRI). Antony William Rix has been the CEO since incorporation. | Director de Operaciones | - | - |
Historial de carrera de Benita Prud’homme
Estadísticas
Internacional
Reino Unido | 2 |
Operativa
Chief Operating Officer | 1 |
Sectorial
Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Lucida Medical Ltd.
![]() Lucida Medical Ltd. Medical SpecialtiesHealth Technology Lucida Medical Ltd. is a start-up based in Cambridge, UK that develops AI-based technology to assist clinicians in finding cancer more accurately, diagnosing and treating it more effectively, and saving time. The company was founded in 2019 by Dr. Antony Rix, an expert in medical devices, machine learning, and AI, and Prof. Evis Sala, who was a professor of oncological imaging at the University of Cambridge & Addenbrookes Hospital at the time. Lucida Medical's first product, Prostate Intelligence™ (PI™), is intended for use to assist in the diagnosis of prostate cancer and has completed regulatory approvals. The British company enables healthcare professionals to find cancer quickly and efficiently with artificial intelligence (AI) and magnetic resonance imaging (MRI). Antony William Rix has been the CEO since incorporation. | Health Technology |
- Bolsa de valores
- Insiders
- Benita Prud’homme
- Experiencia